Janssen starts a new clinical trial as manufacturing issue is addressed

Published: 2017-06-13 16:28:00
Updated: 2017-06-13 10:01:48

Janssen, a multinational pharmaceutical company owning the license of JNJ-64565111, a Hanmi Pharm’s biologic for the treatment of diabetes and obesity, will start a new clinical trial at the end of this year as the ‘manufacturing delay’ issue was addressed.

Hanmi Pharm(CEO Sae-Chang Kwon, Jong-S...


- Email service daily and homepage access.
  1. $300 per month. ($3,240 per year)
  2. 5 Email holders per each company.
  3. Anual contract base.

Original Korean

Address: 295-1, Chungpa-Ro, Yongsan-Gu, Korea
Phone: 02-3270-0114 | Fax: 02-3270-0129 | Email: eyd@yakup.com

Copyright © Yakup Shinmoon, Inc. All Rights Reserved.